Drugs / IC19 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06886919 | Mar → Sep 2025 overdue | systemic lupus erythematosus | Beijing Immunochina Medical Science & Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IC19 CAR-T | “IC19 CAR-T cell therapy” NCT06886919 ↗ |
| Modality | Cell therapy | “IC19 CAR-T cell therapy” NCT06886919 ↗ |